Nagai T, Yamada H
Oriental Medicine Research Center, Kitasato Institute, Tokyo, Japan.
Immunopharmacol Immunotoxicol. 1998 May;20(2):267-81. doi: 10.3109/08923979809038544.
When BALB/c mice were treated with a Kampo (Japanese herbal) medicine "Sho-seiryu-to (SST)" (1 g/kg, 10 times) orally from 7 days before to 5 days after the infection and infected with mouse-adapted influenza virus A/PR/8/34 by nasal-site restricted infection, SST caused increment of the influenza virus hemagglutinin-specific IgA antibody secreting cells in nasal lymphocyte but not in Peyer's patch lymphocyte at 6 days after infection in comparison with water-treated mice. Oral administration of SST also augmented IL-2 receptor beta chain+ (activated) T-cell in Peyer's patch lymphocyte, but not in the nasal lymphocyte. We previously reported that SST showed potent anti-influenza virus activity through augmentation of the antiviral IgA antibody titer in the nasal and broncho-alveolar cavities of the mice (T. Nagai and H. Yamada, 1994, Int. J. Immunopharmacol. 16, 605-613). These results suggest that oral administration of SST shows anti-influenza virus activity in the nasal cavity by activation of T-cell in Peyer's patch lymphocyte and stimulation of production of anti-influenza virus IgA antibody in nasal lymphocyte. When ovalbumin-sensitized allergic pulmonary inflammation model mice were administered orally with SST (1 g/kg) from 8 days before (11 times) or from 2 h after (4 times) to 4 days after the infection and infected with mouse-adapted influenza virus A/PR/8/34, replications of the virus in the both nasal and broncho-alveolar cavities or only nasal cavity were significantly inhibited at 5 days after infection in comparison with water-treated control by augmenting antiviral IgA antibody, respectively. These results suggest that SST is useful for both prophylaxis and treatment of influenza virus infection on patients with allergic pulmonary inflammation, such as bronchial asthma.
将BALB/c小鼠从感染前7天至感染后5天每天口服给予汉方（日本草药）药物“小青龙汤（SST）”（1 g/kg，共10次），并通过鼻腔局部感染接种适应小鼠的甲型流感病毒A/PR/8/34，结果显示，与给予水处理的小鼠相比，感染后6天，SST可使鼻腔淋巴细胞中流感病毒血凝素特异性IgA抗体分泌细胞增多，而派伊尔结淋巴细胞中未见增多。口服SST还可使派伊尔结淋巴细胞中IL-2受体β链阳性（活化）T细胞增多，但鼻腔淋巴细胞中未见增多。我们之前报道过，SST通过提高小鼠鼻腔和支气管肺泡腔中的抗病毒IgA抗体滴度而显示出强大的抗流感病毒活性（T. Nagai和H. Yamada，1994，《国际免疫药理学杂志》16，605 - 613）。这些结果表明，口服SST可通过激活派伊尔结淋巴细胞中的T细胞以及刺激鼻腔淋巴细胞产生抗流感病毒IgA抗体，从而在鼻腔中显示出抗流感病毒活性。当对卵清蛋白致敏的过敏性肺部炎症模型小鼠从感染前8天（共11次）或感染后2小时（共4次）至感染后4天每天口服给予SST（1 g/kg），并接种适应小鼠的甲型流感病毒A/PR/8/34时，与给予水处理的对照相比，感染后5天，病毒在鼻腔和支气管肺泡腔或仅在鼻腔中的复制分别因抗病毒IgA抗体增加而受到显著抑制。这些结果表明，SST对于预防和治疗过敏性肺部炎症患者（如支气管哮喘患者）的流感病毒感染均有效。
